The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

The American Society for Preventive Cardiology (ASPC) announces a full program of events to be held at their annual Congress on Cardiovascular Disease Prevention, scheduled in 2025 ...

Why is India, a nation bursting with brilliant minds and world-class institutions, not leading in transformative scientific ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific BSX. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...

Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...